Los inhibidores de PCSK9, de la innovación a la aplicación clínica sostenib | Rev. esp. cardiol. (Ed. impr.);Rev. esp. cardiol. (Ed. impr.);71(12): 996-998, dic. 2018. | IBECS

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Los inhibidores de PCSK9, de la innovación a la aplicación clínica sostenib / PCSK9 inhibitors: from innovation to sustainable clinical application

Lekuona, Iñaki.

Affiliation

Lekuona, Iñaki; Organización Sanitaria Integrada Barrualde. Hospital Galdakao-Usansolo. Servicio Cardiología. Galdácano. España

Rev. esp. cardiol. (Ed. impr.) ; Rev. esp. cardiol. (Ed. impr.);71(12): 996-998, dic. 2018.

Article in Es | IBECS | ID: ibc-179004

Responsible library: ES1.1

Localization: BNCS

RESUMEN

RESUMEN

No disponible

Subject(s)

Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Proprotein Convertase 9 / Hyperlipoproteinemia Type II / Cholesterol, LDL Limits: Humans Language: Es Journal: Rev. esp. cardiol. (Ed. impr.) Year: 2018 Document type: Article

Search on Google

Full text: 1 Collection: 06-national / ES Database: IBECS Main subject: Proprotein Convertase 9 / Hyperlipoproteinemia Type II / Cholesterol, LDL Limits: Humans Language: Es Journal: Rev. esp. cardiol. (Ed. impr.) Year: 2018 Document type: Article